Telehealth GLP-1 Prescribing: Compliance Requirements in 2026

Telehealth platforms have been among the fastest-growing channels for GLP-1 weight management programs. The combination of convenience, accessibility, and the ongoing demand for compounded semaglutide and tirzepatide has created a significant market opportunity.

But the compliance landscape for telehealth GLP-1 prescribing has become significantly more complex. Platforms that were operating in a relatively permissive environment two years ago are now facing increased regulatory scrutiny from state medical boards, the DEA, and the FTC.

This post covers the key compliance requirements for telehealth platforms prescribing GLP-1 compounds in 2026.

The most fundamental requirement for telehealth GLP-1 prescribing is establishing a valid patient-prescriber relationship. This requirement has not changed — but enforcement has increased.

Requirements vary by state, but generally include:

• Synchronous communication: Most states require a real-time audio-visual encounter (not just an asynchronous questionnaire) to establish a new patient-prescriber relationship
• Clinical evaluation: The prescriber must conduct an appropriate clinical evaluation, including relevant history and assessment
• Documentation: The encounter and clinical rationale must be documented in the patient record
• Follow-up availability: The prescriber must be available for follow-up

Platforms that have been relying on asynchronous questionnaire-only models to establish new patient relationships are operating in increasingly risky territory.

Telehealth prescribing rules vary significantly by state. Some states have enacted specific telehealth practice standards that go beyond federal requirements. Key states to watch:

California: Has specific telehealth prescribing standards and has increased enforcement activity around GLP-1 prescribing.

Florida: Has enacted specific rules around telehealth prescribing for controlled substances and has been active in enforcement.

Texas: Has specific rules around the corporate practice of medicine that affect how telehealth platforms can be structured.

New York: Has specific telehealth prescribing requirements and has been active in reviewing GLP-1 prescribing practices.

The Ryan Haight Online Pharmacy Consumer Protection Act governs online prescribing of controlled substances. While GLP-1 compounds (semaglutide, tirzepatide) are not controlled substances, some compounds that telehealth platforms prescribe alongside GLP-1s (such as certain appetite suppressants) may be.

Platforms that prescribe any controlled substances via telehealth must comply with Ryan Haight Act requirements, including the in-person evaluation requirement (with limited exceptions).

Telehealth platforms face the same supply chain compliance requirements as brick-and-mortar practices — but at scale. Key requirements:

Your compounding supplier must be licensed to ship to every state where your patients are located. A supplier licensed in all 50 states is essential for a national telehealth platform.

For telehealth platforms, the 503A model (patient-specific prescriptions) is the standard pathway. Each prescription must be for a named patient with a valid patient-prescriber relationship.

Some platforms have explored 503B supply models, but this requires careful analysis of whether the platform's model qualifies as a "healthcare facility" for 503B purposes.

Telehealth platforms need systems that can maintain compliant documentation at scale — prescription records, patient-prescriber relationship documentation, and supply chain records for every patient.

The FTC has increased scrutiny of telehealth marketing, particularly around weight loss claims. Requirements:

• Substantiate all claims: Weight loss claims must be supported by competent and reliable scientific evidence
• Disclose material connections: Influencer and affiliate marketing must include appropriate disclosures
• Avoid misleading before/after: The FTC has specific rules about before/after advertising for weight loss
• Subscription cancellation: If you offer subscription models, cancellation must be easy and clearly disclosed

Telehealth platforms operating at scale need supply partners who understand the compliance landscape — not just vendors who process orders.

At MedClinic Partners, our founding team includes mass-tort attorneys who have litigated against pharmaceutical companies and medical operators who have run telehealth platforms. We track regulatory changes across all 50 states and can advise our telehealth clients on compliance developments that affect their operations.

We are licensed in all 50 states and can serve telehealth platforms operating nationally.

Request portal access for your telehealth platform →

This content is for informational purposes only and does not constitute legal advice. Consult with qualified legal counsel regarding your specific compliance obligations.